• PIN23 CLINICAL AND ECONOMIC IMPACT OF HERD IMMUNITY ASSOCIATED WITH HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINATION IN CANADA

    May 1, 2004, 00:00

  • CE2 PANEL ANALYSIS OF CENSORED MEDICAL COST DATA

    May 1, 2004, 00:00

  • CE4 AN ACTUARIAL APPROACH TO ESTIMATING THE STREAM OF COSTS ASSOCIATED WITH BREAST AND COLORECTAL CANCER

    May 1, 2004, 00:00

  • PCV18 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PRAVASTATIN, AND SIMVASTATIN

    May 1, 2004, 00:00

  • PMH55 CHILD HEALTH ILLNESS PROFILE AS A QUALITY OF LIFE MEASURE OF CHILDREN WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER

    May 1, 2004, 00:00

  • PNL21 INSOMNIA IN A NATIONAL AMBULATORY CARE SETTING 2001

    May 1, 2004, 00:00

  • DB4 DRIVERS OF TREATMENT PREFERENCE AMONG INDIVIDUALS WITH TYPE-2 DIABETES

    May 1, 2004, 00:00

  • HM2 MODELS IDENTIFYING VARIABLES INFLUENCING PHYSICIAN ADOPTION OF NEWLY LAUNCHED PHARMACEUTICALS IN THE UNITED STATES

    May 1, 2004, 00:00

  • PIN21 COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2004, 00:00

  • PHP12 FACTORS AFFECTING CONSUMER VIEWS REGARDING GENERIC DRUG SUBSTITUTION PRACTICES- AN EFFECTIVE TOOL TO MANAGE HEALTH CARE COST

    May 1, 2004, 00:00

  • PCV36 THE IMPACT OF ACEI RELATED COUGH-A SURVEY OF AUSTRALIAN PATIENTS

    May 1, 2004, 00:00

  • PMH15 FACTORS ASSOCIATED WITH SECOND-GENERATION ANITPSYCHOTICS IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH BIPOLAR DISORDERS

    May 1, 2004, 00:00

  • PNL23 PROBABILISTIC SENSITIVITY ANALYSIS OF A COSTEFFECTIVENESS MODEL FOR TRIPTANS (5-HT AGONISTS)

    May 1, 2004, 00:00

  • PMD24 EXPECTED VALUE OF SYMMETRY OF INFORMATION-A FRAMEWORK FOR ASSESSING THE POTENTIAL VALUE OF INDIVIDUALIZING CARE BASED ON PATIENT PREFERENCES

    May 1, 2004, 00:00

  • POS3 HEALTH CARE UTILIZATION AND EXPENDITURES- A STUDY OF SEVERE OSTEOPOROSIS

    May 1, 2004, 00:00

  • SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS

    May 1, 2004, 00:00

  • MH3 COST-EFFECTIVENESS OF METHYLPHENIDATE OROS FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)- AN EVALUATION FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

    May 1, 2004, 00:00

  • SC3 FACTORS IMPACTING MAMMOGRAPHY SCREENING IN RURAL AND URBAN AREAS

    May 1, 2004, 00:00

  • PDB20 COST-EFFECTIVENESS OF DULOXETINE VERSUS ROUTINE TREATMENT FOR PAINFUL DIABETIC NEUROPATHY IN A RANDOMIZED TRIAL FROM A SOCIETAL PROSPECTIVE

    May 1, 2004, 00:00

  • PGI6 ECONOMIC BURDEN OF GERD AND PUD IN AN EMPLOYED POPULATION

    May 1, 2004, 00:00

  • PAR4 COST-EFFECTIVENESS OF TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS AS FIRST-LINE AGENTS IN RHEUMATOID ARTHRITIS

    May 1, 2004, 00:00

  • PMH4 ATYPICAL ANTIPSYCHOTIC TREATMENT ADHERENCE AND PERSISTENCE IN A STATE MEDICAID PROGRAM

    May 1, 2004, 00:00

  • PE3 COMORBIDITY INFLUENCE INDEX

    May 1, 2004, 00:00

  • PDB14 PROPENSITY SCORE METHODS FOR REDUCING BIAS IN THE COMPARISON OF COSTS AND UTILIZATION BETWEEN INSULIN LISPRO AND REGULAR INSULIN

    May 1, 2004, 00:00

  • PIN16 COST-EFFECTIVENESS OF FOUR ANTIMICROBIAL REGIMENS IN PATIENTS ADMITTED TO THE MEDICAL FLOOR WITH CLASS IV OR V COMMUNITY-ACQUIRED PNEUMONIA

    May 1, 2004, 00:00

  • PAR17 CHARACTERIZATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS FOR PATIENTS PRESCRIBED TUMOR NECROSIS FACTOR-ALPHA INHIBITORS

    May 1, 2004, 00:00

  • PCV44 BMI, SELF-REPORTED COMORBIDITIES, AGE, AND GENDER DO NOT EXPLAIN COUNTRY-SPECIFIC DIFFERENCES IN OBESITYRELATED QUALITY OF LIFE

    May 1, 2004, 00:00

  • PAR7 ASSESSMENT OF PATIENT-REPORTED OUTCOMES AMONG OSTEOARTHRITIC PATIENTS

    May 1, 2004, 00:00

  • PIN20 BURDEN OF ILLNESS OF BACTERIAL CELLULITIS AND ERYSIPELAS OF THE LEG IN THE NETHERLANDS

    May 1, 2004, 00:00

  • PAR8 THE RELATIONSHIP BETWEEN GASTROINTESTINAL SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN KOREAN PATIENTS WITH RHEUMATIC DISEASES

    May 1, 2004, 00:00

  • AR3 REVALIDATION OF THE ORIGINAL CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) INSTRUMENT

    May 1, 2004, 00:00

  • PDB23 IS PSYCHOLOGICAL GENERAL WELL-BEING AN IMPORTANT PATIENT-REPORTED OUTCOME FOR THE EVALUATION OF DIABETES DRUG THERAPY?

    May 1, 2004, 00:00

  • PPN7 TRENDS IN MEDICAL USE AND ABUSE OF SUSTAINEDRELEASE OPIOID ANALGESICS- A REVISIT

    May 1, 2004, 00:00

  • WORK LOSS AND ACTIVITY IMPAIRMENT DUE TO INFLAMMATORY BOWEL DISEASE

    May 1, 2004, 00:00

  • PCV41 MEDICATION POSSESSION RATIOS FOR PATIENTS WITH CALCIUM CHANNEL BLOCKERS AND/OR STATINS

    May 1, 2004, 00:00

  • HR3 COMPARISON OF REIMBURSEMENT SYSTEMS OF VARIOUS COUNTRIES IN CENTRAL AND EASTERN EUROPE, AFRICA, AND MIDDLE EAST

    May 1, 2004, 00:00

  • PBR1 THE ECONOMIC BURDEN OF ANEMIA IN AN INSURED POPULATION

    May 1, 2004, 00:00

  • PCV23 HEALTH CARE AND DRUG UTILIZATION PATTERNS IN PATIENTS RECEIVING LONG TERM THIENOPYRIDINE THERAPY

    May 1, 2004, 00:00

  • PUK11 PATIENT PERSISTENCY WITH MEDICATIONS FOR OVERACTIVE BLADDER

    May 1, 2004, 00:00

  • PHP5 EVALUATING THE COSTS OF DISEASES IMPUTABLE TO STRESS AT WORK

    May 1, 2004, 00:00

  • CV2 CARDIOVASCULAR RISK OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS COMPARED TO OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS- AN OBSERVATIONAL STUDY OF A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PUK2 A COST COMPARISON ANALYSIS OF TWO CLINICALLY UROSELECTIVE ALPHA BLOCKERS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

    May 1, 2004, 00:00

  • PCN17 THE HEALTH CARE COST OF SMOKING IN CANADA

    May 1, 2004, 00:00

  • PCV60 DISORDERS OF LIPOID METABOLISM- LIKELIHOOD OF PRESCRIPTION THERAPY

    May 1, 2004, 00:00

  • DB1 THE IMPACT OF USING EITHER THE FRAMINGHAM OR THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY RISK FORMULAE IN DIABETES HEALTH ECONOMICS MODELING

    May 1, 2004, 00:00

  • PIN13 AN ECONOMIC AND CLINICAL ASSESSMENT OF FIRST-LINE MONOTHERAPY IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA WITHIN MANAGED CARE

    May 1, 2004, 00:00

  • PDB21 THE IMPACT OF COMMON DIABETIC COMPLICATIONS ON QUALITY OF LIFE

    May 1, 2004, 00:00

  • PMD1 COMPARISON OF GENERALIZED LINEAR MODELS AND ORDINARY LEAST-SQUARES REGRESSION FOR COST ESTIMATION

    May 1, 2004, 00:00

  • CE1 A FRAMEWORK FOR COSTING RECOMMENDATIONS IN PHARMACOECONOMIC GUIDELINES

    May 1, 2004, 00:00

  • PAA20 PREFERENCE SCORES FROM ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) PATIENTS

    May 1, 2004, 00:00

  • ND2 COST-EFFECTIVENESS OF MIGRAINE PREVENTION- RESULTS FROM A MODEL OF TOPIRAMATE TREATMENT

    May 1, 2004, 00:00

  • RX2 PREVALENCE AND CORRELATES OF POTENTIALLY INAPPROPRIATE PRESCRIBING AMONG THE AMBULATORY ELDERLY IN 2001

    May 1, 2004, 00:00

  • PIN15 THE COST OF TREATMENT FAILURE IN ACUTE BACTERIAL MAXILLARY SINUSITIS

    May 1, 2004, 00:00

  • PMH22 CONVENTIONAL ANTIPSYCHOTICS CAN BE COST EFFECTIVE FOR BROADLY DEFINED TREATMENT RESISTANT OR INTOLERANT SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PIN24 ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA, 1997-2001

    May 1, 2004, 00:00

  • AC4 CLINICAL AND ECONOMIC OUTCOMES OF NON-ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PATIENTS WITH HIV

    May 1, 2004, 00:00

  • PSD3 TOTAL HEALTH CARE COSTS FOR BENIGN PROSTATIC HYPERPLASIA PATIENTS ON ALPHA1-BLOCKER TREATMENT IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PCN3 POTENTIAL IMPACT OF WANING OF VACCINE-INDUCED IMMUNITY AGAINST HUMAN PAPILLOMAVIRUS 16/18

    May 1, 2004, 00:00

  • PAA12 RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY USING MULTIVARIATE LOGISTIC REGRESSION

    May 1, 2004, 00:00

  • PHP14 ADDITION OF PHARMACY COST DATA IMPROVES PERFORMANCE OF THE ADJUSTED CLINICAL GROUPS PREDICTIVE MODEL FOR TOTAL HEALTH CARE COSTS OVERALL AND WITHIN DISEASE SPECIFIC GROUPS

    May 1, 2004, 00:00

  • PCN1 EPOETIN ALFA AND DARBEPOETIN ALFA ANEMIA TREATMENT OUTCOMES IN CANCER PATIENTS FROM A VA PERSPECTIVE

    May 1, 2004, 00:00

  • PCV13 RECENT EVIDENCE SURROUNDING THE EFFICACY OF PROTECTED CAROTID ANGIOPLASTY WITH STENTS

    May 1, 2004, 00:00

  • PIN18 DIRECT TREATMENT COSTS OF TINEA CAPITIS AMONG THE UNITED STATES PRIVATELY INSURED POPULATION

    May 1, 2004, 00:00

  • PCV26 MEDICARE EXPENDITURES IN RELATION TO FUNCTIONAL HEALTH STATUS POST-STROKE FOR A NATIONALLY-REPRESENTATIVE SAMPLE OF MEDICARE BENEFICIARIES FROM 1996 TO 2000

    May 1, 2004, 00:00

  • PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS

    May 1, 2004, 00:00

  • PMH52 IMPROVEMENT IN QUALITY-OF-LIFE WITH RISPERIDONE AUGMENTATION IN TREATMENT-RESISTANT DEPRESSION

    May 1, 2004, 00:00

  • PCV15 ECONOMIC EVALUATION OF GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS WITH STENTING

    May 1, 2004, 00:00

  • POS4 COST-EFFECTIVENESS OF LONG-TERM HORMONE REPLACEMENT THERAPY (ESTROGEN PLUS PROGESTIN) IN HEALTHY POSTMENOPAUSAL WOMEN FOR OSTEOPOROSIS PREVENTION

    May 1, 2004, 00:00

  • PAA4 INHALED SALMETEROL UTILIZATION AND ASTHMA PATIENT OUTCOMES IN A GROUP-MODEL MANAGED CARE ORGANIZATION

    May 1, 2004, 00:00

  • PAR2 INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY PRACTICES

    May 1, 2004, 00:00

  • PMH63 TREND AND GEOGRAPHIC VARIATIONS IN THE LENGTH OF STAY FOR SCHIZOPHRENIA IN THE UNITED STATES

    May 1, 2004, 00:00

  • PUK13 VALIDATION OF AUTOMATED DATABASE ALGORITHMS TO IDENTIFY HOSPITAL-ACQUIRED ACUTE RENAL FAILURE

    May 1, 2004, 00:00

  • PAA13 COSTS

    May 1, 2004, 00:00

  • PHP16 FAMILIES, FRIENDS AND COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PCN26 ARE HEALTH STATES 'TIMELESS'? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION USING A REPEATED MEASURES DESIGN

    May 1, 2004, 00:00

  • PMD26 UTILIZATION OF COMPLEMENTARY DATA SOURCES TO DEVELOP INDICATION ALLOCATIONS

    May 1, 2004, 00:00

  • PHP43 THE IMPACT OF PRICE CONTROLS ON PHARMACEUTICAL RD INVESTMENT

    May 1, 2004, 00:00

  • RI4 AN ECONOMIC ANALYSIS OF RAPID TESTS AND ANTIVIRAL TREATMENTS FOR INFLUENZA IN CHILDREN

    May 1, 2004, 00:00

  • PUK7 A COST EVALUATION OF CYCLOPHOSPHAMIDE PLUS PREDNISONE VERSUS AZATHIOPRINE PLUS PREDNISONE FOR TREATMENT OF LUPUS NEPHRITIS

    May 1, 2004, 00:00

  • PMH46 IMPROVEMENTS IN COGNITIVE DEFICITS ARE ASSOCIATED WITH IMPROVED FUNCTIONAL OUTCOMES- RESULTS FROM A LONGITUDINAL OBSERVATIONAL STUDY OF SCHIZOPHRENIA PATIENTS

    May 1, 2004, 00:00

  • PAR10 IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION MEASURES IN RHEUMATOID ARTHRITIS- USE OF ITEM RESPONSE THEORY IN PATIENTS TREATED WITH ABATACEPT (CTLA4IG)

    May 1, 2004, 00:00

  • HP3 EFFECT OF COPAY INCREASE ON FOUR MEASURES OF COMPLIANCE- A NATURAL EXPERIMENT

    May 1, 2004, 00:00

  • PMH18 THE EFFECTS OF OPEN ACCESS ON DRUG THERAPY OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER IN THE CALIFORNIA MEDICAID (MEDI-CAL) PROGRAM

    May 1, 2004, 00:00

  • HM3 PREDICTING PHARMACY COSTS USING HEALTH-RELATED QUALITY-OF-LIFE AND PHARMACY CLAIMS MEASURES IN ADULT ASTHMATICS

    May 1, 2004, 00:00

  • PCO2 IMPACT OF ANEMIA ON HOSPITALIZATION AND MORTALITY IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CHRONIC KIDNEY DISEASE

    May 1, 2004, 00:00

  • PNL18 DEVELOPMENT AND PILOT TESTING OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)-AN INSTRUMENT TO ASSESS FUNCTIONAL HEALTH IN HUNTER SYNDROME

    May 1, 2004, 00:00

  • PMH31 COST AND COMORBIDITIES ASSOCIATED WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PES3 PRIOR AUTHORIZATION OF TOPICAL RETINOIDS NEEDED? EVIDENCE FROM OUTPATIENT US NATIONAL PRACTICE DATA

    May 1, 2004, 00:00

  • PNL12 COST UTILITY ANALYSIS OF INTERFERON BETA-1A (AVONEX) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)

    May 1, 2004, 00:00

  • PCN29 MEASURING CHEMOTHERAPY EFFECTIVENESS IN NATURALISTIC SETTINGS- THE THREE FACES OF RELATIVE DOSE INTENSITY

    May 1, 2004, 00:00

  • PAA5 LOCAL ADVERSE EVENT RATES AND COSTS ASSOCIATED WITH INHALED CORTICOSTEROIDS USE

    May 1, 2004, 00:00

  • PHP34 EXPLICIT INDICATORS TO MEASURE PREVENTABLE DRUG-RELATED MORBIDITY IN AN ELDERLY POPULATION

    May 1, 2004, 00:00

  • PIN25 COSTS AND OUTCOMES OF EXTENDED-RELEASE CLARITHROMYCIN FOR LOWER RESPIRATORY TRACT INFECTIONS

    May 1, 2004, 00:00

  • PCV46 EXPLORATION OF HIGHLY ELEVATED CREATININE KINASE RESULTS AND ASSOCIATED CHOLESTEROL THERAPY IN A LARGE COMMERCIAL HEALTH PLAN

    May 1, 2004, 00:00

  • PMH9 ANALYSIS OF ANTIDEPRESSANT MEDICATION UTILIZATION AND ADHERENCE OF MANAGED CARE PATIENTS ENROLLED IN A MEDICATION ADHERENCE PROGRAM

    May 1, 2004, 00:00

  • PSD1 A SELF-ADMINISTERED SCREENER FOR MALE ERECTILE DISFUNCTION-THE SPANISH VERSION OF THE LIFESATISFACTION CHECK LIST 'LISAT 8'

    May 1, 2004, 00:00

  • PHP37 CONTENT ANALYSIS OF PRINT DIRECT TO CONSUMER DRUG ADVERTISEMENTS TO DETERMINE NUMBER AND SPECIFICITY OF RISK STATEMENTS

    May 1, 2004, 00:00

  • PDB28 GLYCEMIC CONTROL AS A CLINICAL OUTCOME VARIABLE- THE IMPACT OF NON-STANDARDIZED MEASURES

    May 1, 2004, 00:00

  • PCV59 CLINICAL PHARMACIST INVOLVMENT IN COMMUNITY ANTICOAGULATION CONTROL

    May 1, 2004, 00:00

  • PAA6 RACIAL DIFFERENCES IN PHARMACOTHERAPY AND HEALTH CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PAA1 MEASURING THE IMPACT OF AN ASTHMA DISEASE MANAGEMENT INTERVENTION ON PHARMACY AND IN-PATIENT SERVICE UTILIZATION IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PMH26 OUT-OF-POCKET DRUG EXPENDITURES AND PATTERNS OF DEPRESSION IN THE ELDERLY- A 5-YEAR POPULATIONBASED STUDY

    May 1, 2004, 00:00

  • PMH65 SECOND SSRIS SWITCHING AND DISCONTINUATION AFTER FLUOXETINE INITIAL THERAPY

    May 1, 2004, 00:00

  • PMH3 FATORS ASSOCIATED WITH SECOND-GENERATION ANTIPSYCHOITC USE IN THE CALIFORNIA MEDICAID (MEDI-CAL) PATIENTS WITH SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PIN10 OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN) IN A PEDIATRIC UNIT

    May 1, 2004, 00:00

  • AR1 ASSESSING THE COST-EFFECTIVENESS OF COX-2 SPECIFIC INHIBITORS FOR ARTHRITIS IN THE VETERANS HEALTH ADMINISTRATION

    May 1, 2004, 00:00

  • PHP25 ASSESSMENT OF THE IMPACT OF 'ACADEMIC DETAILING' IN PROMOTING COST-EFFECTIVE GENERIC DRUG PRESCRIPTION AMONG AMBULATORY CARE PHYSICIANS IN WEST VIRGINIA

    May 1, 2004, 00:00

  • HR1 DO DRUG PRICES REFLECT VALUE? DO FORMULARY POLICIES?

    May 1, 2004, 00:00

  • PCV3 USING HEALTH-RISK APPRAISAL DATA FOR ASSESSING PREDICTORS OF HYPERTENSION TREATMENT

    May 1, 2004, 00:00

  • CN4 COST-EFFECTIVENESS (CE) ANALYSIS OF INTERFERON-ALPHA IN HIGH-RISK MELANOMA PATIENTS

    May 1, 2004, 00:00

  • PCV10 THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL IN HONG KONG

    May 1, 2004, 00:00

  • PDB5 SELF-MONITORING OF BLOOD GLUCOSE AMONG VETERANS WITH DIABETES MANAGED ON ORAL THERAPY

    May 1, 2004, 00:00

  • PE4 AN AUTOMATED METHOD TO INFER MORBIDITY DESCRIPTIONS FROM PATIENT PHARMACY PROFILES

    May 1, 2004, 00:00

  • PCN9 COST EFFECTIVENESS OF ADDING BISPHOSPHONATES TO THE NON-SURGICAL ANDROGEN DEPRIVATION THERAPY FOR FRACTURE REDUCTION IN PATIENTS WITH NONMETASTATIC PROSTATE CANCER

    May 1, 2004, 00:00

  • PCV34 QUALITY OF LIFE FROM THE MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY

    May 1, 2004, 00:00

  • PMD19 TRAINING REGULATORY AGENCIES IN PRO EVALUATION- THE WORKMATS EXPERIENCE

    May 1, 2004, 00:00

  • PMD10 TESTING AND CORRECTING NON-RANDOM SELECTION BIAS- AN APPLICATION TO CENSORED MEDICAL COST

    May 1, 2004, 00:00

  • PHP20 FACTORS THAT INFLUENCE PRESCRIBING DECISIONS

    May 1, 2004, 00:00

  • PES16 VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DERMATITIS (CHHD)- A PILOT STUDY

    May 1, 2004, 00:00

  • HP2/PAA14 THE EFFECT OF MEDICAID COVERAGE DECISIONS ON NONSEDATING ANTIHISTAMINE UTILIZATION AND SPENDING FOLLOWING OVER-THE-COUNTER AVAILABILITY OF LORATADINE

    May 1, 2004, 00:00

  • PCV58 USE OF GPIIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS

    May 1, 2004, 00:00

  • PMH6 ANTIPSYCHOTIC TREATMENT AND DIABETES IN A PRIVATELY INSURED POPULATION

    May 1, 2004, 00:00

  • PCN24 QUALITY OF LIFE OF NEWLY DIAGNOSED PROSTATE CANCER PATIENTS IN A PUBLIC VS. PRIVATE SETTING

    May 1, 2004, 00:00

  • PCV53 IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS

    May 1, 2004, 00:00

  • CV1 HEALTH PREFERENCES AFTER CABG OR PCI FOLLOWING AN ACUTE MYOCARDIAL INFARCTION

    May 1, 2004, 00:00

  • PMD16 INVESTIGATING THE CEILING EFFECT IN THE EUROQOL IN THE U.S GENERAL POPULATION

    May 1, 2004, 00:00

  • PGI8 A PHARMACOECONOMIC ASSESSMENT OF THE BENEFITS AND COSTS OF MANAGING IMMUNOSUPPRESSION IN POST-LIVER TRANSPLANT PATIENTS-A UNIVERSITY HOSPITAL PERSPECTIVE

    May 1, 2004, 00:00

  • PPN5 AN OPIATE RENEWAL CLINIC-A COST EFFECTIVE APPROACH TO REDUCING UNSCHEDULED PATIENT VISITS

    May 1, 2004, 00:00

  • PCO3 ESTIMATING COST-EFFECTIVENESS OF INHALED CORTICOSTEROIDS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE PRESENCE OF MISSING DATA

    May 1, 2004, 00:00

  • PMH23 COST-EFFECTIVENESS EVALUATION OF LONG-ACTING RISPERIDONE INJECTION

    May 1, 2004, 00:00

  • POS5 ECONOMIC EVALUATION OF SHORT-TERM NON-VERTEBRAL FRACTURE-RELATED COSTS AMONG OSTEOPOROSIS TREATMENTS

    May 1, 2004, 00:00

  • PPN6 RELATIONSHIP BETWEEN PAIN AND PERCEIVED HEALTH STATUS IN OLDER PERSONS WITH POST-HERPETIC NEURALGIA

    May 1, 2004, 00:00

  • PDB17 RETIREE TYPE 2 DIABETES HEALTH CARE COSTS FOR A SELF-INSURED TELECOMMUNICATIONS COMPANY

    May 1, 2004, 00:00

  • PUK5 THE COST-EFFECTIVENESS OF SIROLIMUS WITH CYCLOSPORIN WITHDRAWAL VERSUS LOW DOSE SIROLIMUS AND CONTINUED CYCLOSPORIN WHEN INITIATED WITHIN FOUR MONTHS OF RENAL TRANSPLANTATION

    May 1, 2004, 00:00

  • PIN8 AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING PATTERNS-THE CASE OF METRONIDAZOL USED WHEN INTESTINAL AMOEBIASIS IS SUSPECTED

    May 1, 2004, 00:00

  • Disclosure Information

    May 1, 2004, 00:00

  • OP1 IS THE CURRENT METHOD OF VALUING HEALTH OUTCOMES IN COST-EFFECTIVENESS ANALYSIS VALID?

    May 1, 2004, 00:00

  • RI1 THE EFFECT OF PRESCRIPTION DRUG COVERAGE ON THE COST OF CARE FOR MEDICARE BENEFICIARIES WITH ASTHMA

    May 1, 2004, 00:00

  • PNL5 COST-EFFECTIVENESS ANALYSIS OF RIZATRIPTAN AND SUMATRIPTAN VERSUS CAFERGOT IN THE ACUTE TREATMENT OF MIGRAINE

    May 1, 2004, 00:00

  • PAR3 ECONOMIC EVALUATION OF SELF-INJECTION VS AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS (ETANERCEPT) IN JAPAN

    May 1, 2004, 00:00

  • PDB29 VALIDATION OF THE DIABETES RESOURCE CONSUMPTION INDEX (DRCI)- A RISK ADJUSTMENT TOOL FOR PREDICTING HEALTH CARE RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PAA9 ASTHMA-RELATED HEALTH CARE SERVICES UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV37 HEALTH-RELATED QUALITY OF LIFE OF PATIENTS MAKING AN ATTEMPT AT SMOKING CESSATION

    May 1, 2004, 00:00

  • PDB24 COMPARE USABILITY OF TWO TYPES OF DISPOSABLE PEN (FLEXPEN VERSUS HUMALOG PEN) CONTAINING RAPID-ACTING INSULIN ANALOGUES

    May 1, 2004, 00:00

  • PHP18 PREVALENCE OF DRUG-RELATED PROBLEMS AMONGST HOSPITALISED PATIENTS ON POLYPHARMACY IN SINGAPORE

    May 1, 2004, 00:00

  • PAR1 RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG THERAPY

    May 1, 2004, 00:00

  • PUK10 USING CONJOINT ANALYSIS TO EXAMINE PATIENT QUALITY OF LIFE AND PRESCRIPTION INSURANCE COVERAGE PREFERENCES IN THE MANAGEMENT OF OVERACTIVE BLADDER

    May 1, 2004, 00:00

  • PCO6 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC RESPIRATORY DISEASE

    May 1, 2004, 00:00

  • PHP36 PRESCRIPTION DRUG UTILIZATION PATTERNS AND CHARACTERISTICS FOR A MEDICARE POPULATION IN MANAGED CARE

    May 1, 2004, 00:00

  • PIN33 UTILIZATION PATTERNS OF MEDICAL SERVICES AND PRESCRIPTION DRUGS FOR THE TREATMENT OF TINEA CAPITIS

    May 1, 2004, 00:00

  • PMH47 WEIGHT GAIN AND IMPROVEMENT IN PSYCHOPATHOLOGY DURING TREATMENT OF SCHIZOPHRENIA WITH ANTIPSYCHOTICS AND WITH PLACEBO

    May 1, 2004, 00:00

  • PCV4 VARIABLE PATIENT COMPLIANCE WITH STATINS AND ASSOCIATED LIPID CONTROL AMONG CHINESE PATIENTS WITH HIGH RISK FOR CORONARY HEART DISEASE

    May 1, 2004, 00:00

  • PIN11 TESTING AND TREATMENT OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCN5 ANALYSIS OF OVER 2400 MODERN PHASE I CANCER TRIALS- COMPOSITION, OUTCOMES, AND USE OF SURROGATE ENDPOINTS

    May 1, 2004, 00:00

  • PMH75 DEVELOPMENT OF A PATIENT-REPORTED INSTRUMENT TO ASSESS THE FUNCTIONAL STATUS OF PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMH10 PEDIATRIC ANTIDEPRESSANT PRESCRIPTION PATTERNS

    May 1, 2004, 00:00

  • PMH14 CANADIAN NETWORK FOR BIPOLAR DISORDER (CAN-BD)- FREQUENCY OF RELAPSE IN AN OBSERVATIONAL STUDY

    May 1, 2004, 00:00

  • HR2 DECISION-MAKERS PERCEPTIONS OF ACCESS TO HIGH COST DRUGS (HCDS) IN PUBLIC HOSPITALS IN AUSTRALIA

    May 1, 2004, 00:00

  • PNL9 COST EFFECTIVENESS ANALYSIS OF INTERFERON BETA-1A (AVONEX) IN PRE-CLINICALLY DEFINITE MULTIPLE SCLEROSIS (CDMS)

    May 1, 2004, 00:00

  • PMH35 SERVICE UTILIZATION AND COSTS FOR BIPOLAR DEPRESSION

    May 1, 2004, 00:00

  • PIN14 ECONOMIC COST STRUCTURE OF SEVERE SEPSIS MANAGEMENT

    May 1, 2004, 00:00

  • PCN28 GAPS IN COLORECTAL CANCER OUTCOMES RESEARCH

    May 1, 2004, 00:00

  • PE2 THE EFFECTS OF ANTIDEPRESSANT DRUGS ON THE RISK OF COLORECTAL CANCER-A POPULATION-BASED CASE-CONTROL STUDY

    May 1, 2004, 00:00

  • CN4 COST-EFFECTIVENESS OF ANASTROZOLE VS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC)- A UK NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE

    May 1, 2004, 00:00

  • PMH53 HOSPITALIZATION RATES DURING COMBINATION THERAPY WITH ATYPICAL ANTIPSYCHOTICS IN BIPOLAR DISORDER

    May 1, 2004, 00:00

  • RX4 A DYNAMIC MODEL OF BUDGET IMPACT ANALYSES

    May 1, 2004, 00:00

  • PCV56 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERTENSION

    May 1, 2004, 00:00

  • PNL17 VALIDATION OF THE CHILDHOOD HEALTH ASSESSMENT QUESTIONNAIRE (CHAQ) IN HUNTER SYNDROME

    May 1, 2004, 00:00

  • PMD27 THE APPLICATION OF TWO PRODUCTIVITY INSTRUMENTS AT A LARGE EMPLOYER

    May 1, 2004, 00:00

  • PCV52 IMPACT OF MARKET FORCES ON STATIN PERSISTENCE PATTERS IN A CALIFORNIA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PDB25 PAIN SEVERITY AFFECTS PERCEIVED HEALTH STATUS IN PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHY

    May 1, 2004, 00:00

  • PMH29 COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS CITALOPRAM IN THE TREATMENT OF SEVERE DEPRESSION IN AUSTRIA

    May 1, 2004, 00:00

  • PMH62 HOSPITAL UTILIZATION FOLLOWING AN OPEN ACCESS POLICY FOR ATYPICAL ANTIPSYCHOTIC MEDICATIONS FOR PATIENTS WITH SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PGI4 INPATIENT COSTS OF LIVER CIRRHOSIS IN THE UNITED STATES- A RETROSPECTIVE CLAIMS DATA ANALYSIS, 1993-2001

    May 1, 2004, 00:00

  • PCV25 TOBACCO COST-EFFECTIVENESS ANALYSES AND THE PAYER- IS THE SHORT TERM LONG OVERDUE?

    May 1, 2004, 00:00

  • PUK1 REACHING TARGET HEMATOCRITS WITH EPOETIN- IS THE INFERENCE OF A SURVIVAL BENEFIT VALID?

    May 1, 2004, 00:00

  • PAA8 THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE UTILIZATION

    May 1, 2004, 00:00

  • RX1 CLAIM-BASED DRUG WASTAGE ESTIMATION-HOW HIDDEN REFILL BEHAVIOR CAN HELP

    May 1, 2004, 00:00

  • PNL10 COST-EFFECTIVENESS OF SCREENING FOR NEUTRALIZING ANTIBODIES TO INTERFERON BETAS IN THE TREATMENT OF MULTIPLE SCLEROSIS

    May 1, 2004, 00:00

  • PMH32 COMPARISON OF BIPOLAR DISORDER-RELATED COSTS AMONG PATIENTS WITH AND WITHOUT COMORBID DIABETES

    May 1, 2004, 00:00

  • PCN16 ECONOMIC BURDEN OF PROSTATE CANCER AMONG HOSPITALIZED PATIENTS

    May 1, 2004, 00:00

  • PMH74 COMPARING PSYCHOMETRIC PROPERTIES OF SELF-VERSUS INTERVIEWER-RATED INSTRUMENTS USED IN CLINICAL TRIALS FOR PATIENTS WITH ANXIETY DISORDERS

    May 1, 2004, 00:00

  • PHP40 POST-LAUNCH STUDIES-WHAT IS DESIRABLE, WHAT IS FEASIBLE?

    May 1, 2004, 00:00

  • PCV54 IMPACT OF THE NATIONAL SERVICE FRAMEWORK (NSF) FOR CORONARY ARTERY DISEASE (CAD) ON PHYSICIAN COMPLIANCE OF PRESCRIBING ASPIRIN AND STATINS FOR SECONDARY PREVENTION IN THE UNITED KINGDOM (UK)

    May 1, 2004, 00:00

  • PHP22 TRENDS IN APPROVALS BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE

    May 1, 2004, 00:00

  • PMH40 COST-EFFECTIVENESS OF RITALINTM VERSUS ADDERALLTM FOR FIRST-LINE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN

    May 1, 2004, 00:00

  • PGI1 GASTROINTESTINAL ADVERSE EVENTS FROM NON STEROIDAL ANTI-INFLAMMATORY DRUGS- RELATIONSHIPS BETWEEN RISK ASSESSMENT, VETERANS AFFAIRS PRESCRIBING GUIDELINES, AND HOSPITALIZATION COSTS

    May 1, 2004, 00:00

  • HM1 INDIVIDUALIZED PREDICTIVE DISEASE MODELING AS A TOOL TO IMPROVE EFFICACY AND EFFICIENCY OF DISEASE MANAGEMENT PROGRAMS FOR DIABETES MELLITUS

    May 1, 2004, 00:00

  • PCV14 A COMPARISON OF THE RISK OF ADVERSE THROMBOEMBOLIC AND BLEEDING EVENTS BETWEEN SUBJECTS TREATED AND NOT TREATED WITH WARFARIN

    May 1, 2004, 00:00

  • PHP9 RELATIONSHIP BETWEEN PATIENT-REPORTED READINESS, SELF-MANAGEMENT BEHAVIOR, AND HEALTH STATUS IN MANAGED-CARE PATIENTS WITH CHRONIC CONDITIONS

    May 1, 2004, 00:00

  • PCO5 ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN A STATE HEALTH INSURANCE PROGRAM

    May 1, 2004, 00:00

  • PCN22 THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE CORE QUESTIONNAIRE (EORTC QLQ-C30)- VALIDATION OF ENGLISH VERSION IN SINGAPORE

    May 1, 2004, 00:00

  • PCV45 MECHANICAL AND ALLERGIC ADVERSE EVENTS RELATED TO CENTRAL VASCULAR CATHETERS- EPIDEMIOLOGY IN THE MEDICARE HOSPITALIZED SURGICAL POPULATION, 2002

    May 1, 2004, 00:00

  • PHP32 HEALTH-RELATED QUALITY OF LIFE AND HEALTH PREFERENCE AS PREDICTORS OF MORTALITY AMONG OLDER PEOPLE AT VETERAN HOME

    May 1, 2004, 00:00

  • PAR18 RACIAL DISPARITIES IN PRESCRIBING OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS OVER OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS IN A MEDICAID MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • AC3 COMPARISION OF ADHERENCE TO ANTIHYPERTENSIVES IN A MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • PMD4 ISHIKAWA CAUSE AND EFFECT DIAGRAMS-A USEFUL TOOL IN DESIGNING ECONOMIC ANALYSES

    May 1, 2004, 00:00

  • PHP8 PEER PRESSURE IN HEALTH CARE

    May 1, 2004, 00:00

  • PHP39 STOCK MARKET VALUATION AND FIRM-LEVEL DETERMINANTS OF INNOVATIVE ACTIVITY IN THE PHARMACEUTICAL INDUSTRY

    May 1, 2004, 00:00

  • PUK1 OVERACTIVE BLADDER- AN UNDERESTIMATED AND GROWING DISEASE BURDEN

    May 1, 2004, 00:00

  • PES11 A COST COMPARISON OF TOPICAL 5% FLUOROURACIL VS. CRYOSURGERY FOR THE TREATMENT OF ACTINIC KERATOSIS

    May 1, 2004, 00:00

  • PAA16 PREDICTORS OF SELF-REPORTED ADHERENCE IN PATIENTS WITH ASTHMA

    May 1, 2004, 00:00

  • PMH12 THE IMPACT OF PREMATURE DISCONTINUATION OF ANTIDEPRESSANT THERAPY IN MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PCO1 SMOKING BEHAVIOR AMONG COPD PATIENTS, SASKATCHEWAN CANADA

    May 1, 2004, 00:00

  • PIN28 MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS IN FRANCE

    May 1, 2004, 00:00

  • THE ECONOMIC BURDEN OF TYPE 2 DIABETES MANAGEMENT BY ETHNIC GROUP IN THE TEXAS MEDICAID POPULATION- DB2/PDB19

    May 1, 2004, 00:00

  • PES17 IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [DSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394

    May 1, 2004, 00:00

  • PDB13 PHARMACY AND MEDICAL RESOURCE UTILIZATION AMONG INITIAL METFORMIN AND THIAZOLIDINEDIONE PATIENTS

    May 1, 2004, 00:00

  • PGI12 EVALUATING THE GERD SYMPTOM AND MEDICATION QUESTIONNAIRE (GERD-SMQ) IN A CLINICAL TRIAL

    May 1, 2004, 00:00

  • PMH61 TRENDS IN ANTIPSYCHOTIC PRESCRIBING TO CHILDREN AND ADOLESCENTS- 1996 TO 2001

    May 1, 2004, 00:00

  • PCV40 ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN CORONARY ARTERY DISEASE USING QUALITY INDICATORS

    May 1, 2004, 00:00

  • HP4 CHALLENGES FOR EXAMINING THE ECONOMICS OF PHARMACOGENOMICS

    May 1, 2004, 00:00

  • PBR3 THE HEALTH-RELATED QUALITY OF LIFE EXPERIENCES OF YOUNG ADULTS WITH SICKLE CELL DISEASE- A QUALITATIVE ASSESSMENT

    May 1, 2004, 00:00

  • PIN30 SUBSTITUTION TO LOPINAVIR/RITONAVIR (LPV/R) IS ASSOCIATED WITH IMPROVED PATIENT-REPORTED FATIGUE IN HIV+ PATIENTS EXPERIENCING SIDE EFFECTS RELATED TO THEIR PROTEASE INHIBITOR (PI)/NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI ...

    May 1, 2004, 00:00

  • PIN2 RETREATMENT RATES OF ACUTE OTITIS MEDIA IN PATIENTS WITH TYMPANOSTOMY TUBES WITHIN THE LOUISIANA MEDICAID PROGRAM

    May 1, 2004, 00:00

  • CN1 THE STATE OF THE SCIENCE OF HRQOL ASSESSMENT IN CANCER- FINDINGS FROM THE CANCER OUTCOMES MEASUREMENT WORKING GROUP

    May 1, 2004, 00:00

  • PGI9 RESPONSIVENESS TO CHANGE AND ENGLISH LANGUAGE VALIDATION OF THE WPAI-GERD QUESTIONNAIRE-RESULTS FROM A CANADIAN STUDY

    May 1, 2004, 00:00

  • POS7 COST-EFFECTIVENESS OF TERIPARATIDE (FORTEO) IN THE PREVENTION OF OSTEOPOROTIC FRACTURES AMONG MEN AND POSTMENOPAUSAL WOMEN IN AUSTRALIA

    May 1, 2004, 00:00

  • PHP26 CCOHTA GUIDELINES FOR THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES- CANADA 2004

    May 1, 2004, 00:00

  • MH2 IMPACT OF OPEN ACCESS TO ATYPICAL ANTIPSYCHOTICS IN CALIFORNIA MEDICAID

    May 1, 2004, 00:00

  • PMH60 ANALYSIS OF LONGITUDINAL CLAIMS DATA TO EXAMINE FIRST AND SECOND-LINE USE OF PEMOLINE (CYLERT)

    May 1, 2004, 00:00

  • SC1 PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC) SCREENING STRATEGIES

    May 1, 2004, 00:00

  • PAA3 WEB-ENABLED ASTHMA APPLICATION FOR PERSONALIZED MEDICAL COMMUNICATION WITHIN A MULTI-GROUP PRACTICE SETTING

    May 1, 2004, 00:00

  • PSD2 ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION (ADSD) IN EUROPE-A PRELIMINARY INVESTIGATION

    May 1, 2004, 00:00

  • PAR12 PATIENT PREFERENCE AND WILLINGNESS-TO-PAY FOR VIOXX AS A TREATMENT FOR OSTEOARTHRITIS RELATIVE TO NSAIDS

    May 1, 2004, 00:00

  • PES15 A COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) WITH MONOCULAR VERSUS BILATERAL DISEASE

    May 1, 2004, 00:00

  • PDB7 ALTERNATIVE ANTIPSYCHOTIC TREATMENT AND RISK OF DIABETES- RESULTS FROM NC MEDICAID POPULATION

    May 1, 2004, 00:00

  • PHP35 JUDGMENT RULES IN OLDER ADULTS EVALUATIONS OF DRUG BENEFIT PLANS

    May 1, 2004, 00:00

  • PDB10 UTILIZATION PATTERNS OF DRUGS AND HEALTH CARE SERVICES AMONG RECIPIENTS WITH DIABETES IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PAA15 INVESTIGATION OF THE DETERMINANTS OF ADHERENCE IN ASTHMA USING Q METHODOLOGY

    May 1, 2004, 00:00

  • PMH38 EPILEPSY PATIENTS WITH ATTENTIONDEFICIT/HYPERACTIVITY DISORDER- PREVALENCE AND COST OF CARE

    May 1, 2004, 00:00

  • PMH41 SUICIDE ATTEMPTS BY THE ELDERLY- HOSPITAL RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • ISPOR's “Code of Ethics for Researchers”- Is It Ethical?

    Mar 1, 2004, 00:00

  • Cost-Effectiveness Analysis of Interventions to Enhance Mammography Compliance Using Computer Modeling (CAN*TROL)

    Mar 1, 2004, 00:00

  • Seniors with Chronic Health Conditions and Prescription Drugs- Benefits, Wealth, and Health

    Mar 1, 2004, 00:00

  • ISPOR Code of Ethics for Researchers Background Article—Report of the ISPOR Task Force on Code of Ethics for Researchers

    Mar 1, 2004, 00:00

  • The SCOPE Study- Health-Care Consumption Related to Patients with Chronic Obstructive Pulmonary Disease in France

    Mar 1, 2004, 00:00

  • Inconsistency in DTCA Practices by Manufacturers- Is It Time to Standardize Print Summaries?

    Mar 1, 2004, 00:00

  • Out-of-Pocket Health-Care Expenditures among Older Americans with Cancer

    Mar 1, 2004, 00:00

  • What Is Next for Pharmacoeconomics and Outcomes Research in Asia?

    Mar 1, 2004, 00:00

  • A Computer Simulation Model of the Natural History and Economic Impact of Chronic Obstructive Pulmonary Disease

    Mar 1, 2004, 00:00

  • The Impact of Managed Eye Care on Use of Vision Services, Vision Costs, and Patient Satisfaction

    Mar 1, 2004, 00:00

  • Resource Utilization and Costs of Stroke Unit Care in Germany

    Mar 1, 2004, 00:00

  • Satisfaction with Medication- An Overview of Conceptual, Methodologic, and Regulatory Issues

    Mar 1, 2004, 00:00

  • Assessment of Health-Related Quality of Life in Children- A Review of Conceptual, Methodological, and Regulatory Issues

    Jan 1, 2004, 00:00

  • A Pharmacoeconomic Evaluation of Seven-Valent Pneumococcal Conjugate Vaccine in Spain

    Jan 1, 2004, 00:00

  • Modeling the Efficiency of Reaching a Target Intermediate End Point- A Case Study in Type 2 Diabetes in the United States

    Jan 1, 2004, 00:00

  • Outcomes Research in Health Care- Simulations to Drive Cost Conclusions

    Jan 1, 2004, 00:00

  • Cost-Effectiveness versus Cost–Utility Analysis of Interventions for Cancer- Does Adjusting for Health-Related Quality of Life Really Matter?

    Jan 1, 2004, 00:00

  • Proposal of Polish Guidelines for Conducting Financial Analysis and Their Comparison to Existing Guidance on Budget Impact in Other Countries

    Jan 1, 2004, 00:00

  • The Impact of Olanzapine, Risperidone, or Haloperidol on the Cost of Schizophrenia Care in a Medicaid Population

    Jan 1, 2004, 00:00

  • A Comprehensive Strategy for the Interpretation of Quality-of-Life Data Based on Existing Methods

    Jan 1, 2004, 00:00

  • Relationships of Clinical, Psychologic, and Individual Factors with the Functional Status of Neck Pain Patients

    Jan 1, 2004, 00:00

  • Using Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome Patients- A Cost–Utility Analysis in Spain

    Jan 1, 2004, 00:00

  • Letter to the Editor

    Jan 1, 2004, 00:00

  • CV7 COST-EFFECTIVENESS OF A NEW ANTITHROMBOTIC AGENT- A COMPARISON ACROSS COUNTRIES OF THROMBOPROPHYLAXIS WITH FONDAPARINUX FOLLOWING MAJOR ORTHOPAEDIC SURGERY

    Nov 1, 2003, 00:00

  • PSN2 EFFECTIVITY AND SAFETY OF TACALCITOL IN PSORIASIS VULGARIS IN SPANISH PATIENTS

    Nov 1, 2003, 00:00

  • PCV52 ECONOMIC ANALYSIS OF THE USE OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT STSEGMENT ELEVATION (ACS) FROM THE RUSSIAN HEALTH CARE SYSTEM PERSPECTIVE

    Nov 1, 2003, 00:00

  • PHL7 COST OF TREATMENT (COT) FOR VENOUS LEG ULCERS IN SWEDEN AND THE UK-ESTIMATES FROM CLINICAL EXPERT PANELS AND MODEL SIMULATIONS

    Nov 1, 2003, 00:00

  • PMH8 PREVALENCE AND MEDICAL CARE COSTS OF ANXIETY DISORDERS IN THE UNITED STATES- A NATIONAL ESTIMATE USING THE MEDICAL EXPENDITURE PANEL SURVEY

    Nov 1, 2003, 00:00

  • PCV33 THE COST-EFFECTIVENESS OF TARKA IN THE TREATMENT OF HEART FAILURE AFTER MYOCARDIAL INFARCTION IN THE US HEALTH CARE SETTING

    Nov 1, 2003, 00:00

  • PIN13 COST-EFFECTIVENESS OF VORICONAZOLE COMPARED WITH CONVENTIONAL AMPHOTERICIN B IN FIRST LINE TREATMENT OF INVASIVE ASPERGILLOSIS IN BELGIUM

    Nov 1, 2003, 00:00

  • PCV35 BURDEN OF HYPERCHOLESTEROLEMIA IN GERMANY

    Nov 1, 2003, 00:00

  • ME4 HOW FREQUENTLYARE ECONOMIC EVALUATIONS USED IN DECISION MAKING?

    Nov 1, 2003, 00:00

  • HP3 END STAGE RENAL DISEASE IN FRANCE- PLANNING EVOLUTION OF HEALTH CARE NEEDS USING A MARKOV MODEL

    Nov 1, 2003, 00:00

  • CE1 COST-EFFECTIVENESS MODEL OF RECOMBINANT HUMAN CHORIONIC GONADOTROPIN (R-HCG) VERSUS URINARY HCG (U-HCG) FOR ASSISTED REPRODUCTIVE TECHNIQUES (ART) IN THE USA

    Nov 1, 2003, 00:00

  • PCV53 MANAGEMENT OF THE PRIMARY CARE HYPERCHOLESTEROLEMIC PATIENTS THROUGH A CLINICAL DECISION SUPPORT SYSTEM. OPTIMCARE STUDY REPORT

    Nov 1, 2003, 00:00

  • PCN12 BUDGET IMPACT ANALYSIS OF ANASTROZOLE AS ADJUVANT THERAPY IN THE TREATMENT OF EARLY BREAST CANCER IN THE UK

    Nov 1, 2003, 00:00

  • PMD39 DESCRIPTION OF THE PRINCIPLES OF GOOD PRACTICE FOR TRANSLATION AND CULTURAL ADAPTATION OF PRO MEASURES- ISPOR QOLSIG GROUP

    Nov 1, 2003, 00:00

  • PIN31 COST-EFFECTIVENESS ANALYSIS OF ONCEDAILY MODIFIED RELEASE CLARITHROMYCIN VERSUS CONVENTIONAL TWICE-DAILY GENERIC CLARITHROMYCIN FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

    Nov 1, 2003, 00:00

  • PCV60 INTRODUCTION OF ROSUVASTATIN WILL ENABLE MORE PATIENTS TO ACHIEVE GUIDELINE LDL-C GOALS WITHIN A FIXED BUDGET IN THE UK

    Nov 1, 2003, 00:00

  • PIN36 COST-EFFECTIVENESS OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PROPHYLAXIS AMONG PRETERM INFANTS IN POLAND

    Nov 1, 2003, 00:00

  • PUK14 'EFFECT SIZE' OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH CHRONIC ALLOGRAFT NEPHROPATHY AND ANEMIA TREATED WITH RH-EPO

    Nov 1, 2003, 00:00

  • PMD18 INDIRECT COSTS OF A LARGE-SCALE IMMUNIZATION PROGRAM-WHEN COSTS EXCEED SAVINGS

    Nov 1, 2003, 00:00

  • PCV14 EFFECTIVENESS OF SELF-MEASUREMENT OF BLOOD PRESSURE IN HYPERTENSIVE PATIENTS. DIOAMPA STUDY

    Nov 1, 2003, 00:00

  • PMH3 EVALUATION OF MEDICAL DIAGNOSES FOR TEXAS MEDICAID PATIENTS PRESCRIBED ATYPICAL ANTIPSYCHOTIC MEDICATIONS

    Nov 1, 2003, 00:00

  • PMD26 COST-ASSESSMENT RE-CONSIDERED- THE CASE OF HIP FRACTURE

    Nov 1, 2003, 00:00

  • PUK1 THE USE OF A URINARY CATHETER REMINDER TO REDUCE URINARY CATHETERIZATION IN HOSPITALIZED PATIENTS

    Nov 1, 2003, 00:00

  • PRP15 DO RESPIRATORY DRUGS REDUCE HOSPITAL ADMISSIONS? AN ECOLOGICAL STUDY CARRIED OUT IN MODENA, ITALY, TO INVESTIGATE DISTRICTS VARIABILITY

    Nov 1, 2003, 00:00

  • PCV10 IMPROVED COMPLIANCE AND PERSISTENCE WITH ATORVASTATINE THROUGH A PHARMACY-BASED INTERVENTION

    Nov 1, 2003, 00:00

  • PCV19 A PROBABILISTIC MODEL TO ASSESS THE COST-EFFECTIVENESS OF A NEW STATIN (ROSUVASTATIN) IN THE UK

    Nov 1, 2003, 00:00

  • PAE15 A MULTI-CENTER RETROSPECTIVE STUDY OF RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH GLAUCOMA MANAGEMENT IN FRANCE AND SWEDEN

    Nov 1, 2003, 00:00

  • PDB13 PREDICTORS OF EMERGENCY DEPARTMENT VISITS IN ELDERLY PATIENTS WITH DIABETES

    Nov 1, 2003, 00:00

  • PAE18 IMPROVEMENT IN VISION TARGETED QUALITY OF LIFE (QOL) AFTER CATARACT SURGERY WITH IMPLANTATION OF ACRYSOF NATURAL INTRAOCULAR LENS (IOL)

    Nov 1, 2003, 00:00

  • VV1 RISK ADJUSTMENT AND REFERENCE POINTS

    Nov 1, 2003, 00:00

  • PDB16 COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER- PHARMACOECONOMIC ANALYSIS OF THE MARVAL TRIAL-THE CASE OF GERMANY

    Nov 1, 2003, 00:00

  • PHL5 HEALTH ECONOMIC ANALYSIS OF A SILVER CONTAINING HYDROACTIVATED FOAM DRESSING IN DELAYED HEALING LEG ULCERS

    Nov 1, 2003, 00:00

  • PCV1 PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION, ELEVATED TROPONIN T LEVELS AND DIABETES MELLITUS. OUTCOME AT THREE MONTHS

    Nov 1, 2003, 00:00

  • QL6 PERFORMANCE OF THE EQ-5D IN PATIENTS WITH IRRITABLE BOWEL SYNDROME

    Nov 1, 2003, 00:00

  • GL4 A RANDOMIZED TRIAL OF MEDICAL CO-PRESCRIPTION OF HEROIN TO CHRONIC, TREATMENT-RESISTANT HEROIN ADDICTS IN THE NETHERLANDS- DATA ON QALYS

    Nov 1, 2003, 00:00

  • PIN1 PHARMACEUTICAL MANAGEMENT OF NEWLY HIV DIAGNOSED PATIENTS- RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT

    Nov 1, 2003, 00:00

  • PRP5 COST-EFFECTIVENESS OF SALMETEROL/FLUTICASONE PROPIONATE COMBINATION PRODUCT 50/100 MCG TWICE DAILYAND BUDESONIDE 400 MCG TWICE DAILY IN THE TREATMENTOF ADULTS WITH ASTHMA IN CHINA

    Nov 1, 2003, 00:00

  • PMD4 DIFFERENCES IN PATIENT BURDEN BETWEEN ENDOANAL MRI, DEFECOGRAPHY AND ANORECTAL FUNCTIONAL TESTING FOR PATIENTS WITH FAECAL INCONTINENCE

    Nov 1, 2003, 00:00

  • PMD14 WILLINGNESS TO PAY, WILLINGNESS TO WAIT, AND SUPER QALYS- NARROWING THE CONCEPTUAL GAP BETWEEN CARDINAL AND ORDINAL HEALTH UTILITY MEASURES

    Nov 1, 2003, 00:00

  • CV11 CONTROLRISC STUDY- EVALUATION OF THE MODIFICATION IN CARDIOVASCULAR RISK IN HYPERTENSIVE PATIENTS IN PRIMARY CARE THROUGH PATIENT PERSONALIZED EDUCATION

    Nov 1, 2003, 00:00

  • PHP25 MECHANISMS AND OUTCOMES OF UTILIZATION REVIEW CONDUCTED AMONG PHIC-ACCREDITED HEALTH CARE FACILITIES IN THE PHILIPPINES

    Nov 1, 2003, 00:00

  • MH1 COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPY, COGNITIVE BEHAVIOUR THERAPY AND THEIR COMBINATION FOR PEOPLE WITH BULIMIA NERVOSA IN THE UK

    Nov 1, 2003, 00:00

  • PCV32 COSTS OF HOSPITALIZATION IN DEPARTMENT OF CARDIOLOGY FOR PATIENTS WITH SYSTOLIC HEART FAILURE IN FRANCE

    Nov 1, 2003, 00:00

  • PCN8 PHARMACO-ECONOMIC ASSESSMENT OF CAPECITABINE ORAL CHEMOTHERAPY VERSUS FUFOL MAYO CLINIC CHEMOTHERAPY IN THE TREATMENT OF COLORECTAL CANCER

    Nov 1, 2003, 00:00

  • PMH13 AFFECTIVE PSYCHOSES IN ADOLESCENTS-THE ECONOMIC CONSEQUENCES OF ACUTE CARE HOSPITAL ADMISSIONS OVER THREE YEARS

    Nov 1, 2003, 00:00

  • PCV45 LONG-TERM COST-EFFECTIVENESS OF PRIMARY ANGIOPLASTY COMPARED TO FIBRINOLYSIS IN ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • CP4 LONG-TERM PERSISTENCE WITH STATIN THERAPY IN DAILY MEDICAL PRACTICE

    Nov 1, 2003, 00:00

  • PHL13 THE USE OF A CONDITION-SPECIFIC QUALITY OF LIFE MEASURE (QUALITY OF LIFE-ASSESSMENT FOR GROWTH HORMONE DEFICIENCY IN ADULTS) IN A GENERAL POPULATION

    Nov 1, 2003, 00:00

  • PUK16 LOWER IMPACT ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN ELDERLY PATIENS STARTING AND AFTER ONE YEAR OF HEMODIALYSIS (HD) THAN IN YOUNGER PATIENS-A PROSPECTIVE STUDY

    Nov 1, 2003, 00:00

  • PPN6 CRITICAL PATHWAY STATUS- A COMPARISON OF PATIENT OUTCOMES

    Nov 1, 2003, 00:00

  • PUK10 A COST ANALYSIS OF ALFUZOSIN IN THE MANAGEMENT OF ACUTE URINARY RETENTION

    Nov 1, 2003, 00:00

  • PRP6 COST OF ASTHMA EXACERBATION IN THE HOSPITAL SETTING IN SPAIN

    Nov 1, 2003, 00:00

  • ME1 ASSESSING GENERALISABILITY OF COST-EFFECTIVENESS ESTIMATES IN MULTINATIONAL STUDIES- APPLICATION TO A TRIAL OF MOXIFLOXACIN IN COMMUNITY-ACQUIRED PNEUMONIA (CAP)

    Nov 1, 2003, 00:00

  • PMD11 SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO PHYSICIANS AT THE POINT-OFCARE, OFFER AN IMPORTANT COMPLEMENT TO TRADITIONAL EFFICACY DATA AND ENABLE THE DERIVATION OF PRACTICE-WIDE TREATMENT GUIDELINES

    Nov 1, 2003, 00:00

  • CS1 A MARKOV MODELLED PHARMACOECONOMIC ANALYSIS OF BIMATOPROST 0.03% (LUMIGAN) IN THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION AS AN ALTERNATIVE TO FILTRATION SURGERY IN ITALY

    Nov 1, 2003, 00:00

  • PSN3 MANAGEMENT AND SOCIO ECONOMIC IMPACT OF ATOPIC DERMATITIS (AD) IN FRANCE-THE ELIPANEL STUDY

    Nov 1, 2003, 00:00

  • PAE11 ECONOMIC EVALUATION OF LATANOPROST AS FIRST LINE GLAUCOMA THERAPY IN 6 EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PPN4 EPIDEMIOLOGY, CO-MORBIDITY, AND IMPACT ON HEALTH-RELATED QUALITY OF LIFE OF SELF-REPORTED HEADACHE AND MUSCULOSKELETAL PAIN-A GENDER PERSPECTIVE

    Nov 1, 2003, 00:00

  • PCV31 ECONOMIC EVALUATION OF CLOPIDOGREL IN SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS IN HUNGARY

    Nov 1, 2003, 00:00

  • PAE19 RESEARCH 5134- PREVALENCE AND BURDEN OF BLINDNESS, LOW VISION AND VISUAL IMPAIRMENT IN THE COMMUNITY-A NATIONWIDE SURVEY

    Nov 1, 2003, 00:00

  • MH4 CHILDREN WITH ADHD (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER)- HEALTH CARE USE AND SOCIAL BURDEN ON THE FAMILY

    Nov 1, 2003, 00:00

  • PMH20 TREATMENT WITH PSYCHOSTIMULANTS IS ASSOCIATED WITH DECREASED RATES OF SUBSTANCE ABUSE AND IMPROVED SCHOOL OUTCOMES AMONG CHILDREN WITH AD/HD

    Nov 1, 2003, 00:00

  • PAR12 ADAPTATION OF THE RAQOL FOR ESTONIA

    Nov 1, 2003, 00:00

  • PMD15 THE INTERNATIONAL COSTING SOURCES DATABASE- A TOOL FOR ENSURING CONSISTENT AND RIGOROUS INTERNATIONAL COSTING

    Nov 1, 2003, 00:00

  • MS1 FINANCING PHARMACEUTICAL RD- THE ASSOCIATION WITH SALES

    Nov 1, 2003, 00:00

  • PHL6 TREATMENT OF LEG ULCERS IN SWEDEN STILL DEMANDS LARGE RESOURCES IN SPITE OF IMPROVED MANAGEMENT-THE COST OF ILLNESS (COI) ESTIMATED FROM A PATIENT SURVEY AND PUBLISHED EPIDEMIOLOGICAL STUDIES

    Nov 1, 2003, 00:00

  • PMD31 DECISION-ANALYTIC MODELING IN PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PRP18 ANALYSIS OF LONGITUDINAL CHANGES IN QUALITY OF LIFE BEFORE AND AFTER LUNG TRANSPLANTATION USING A MULTI-LEVEL MODEL

    Nov 1, 2003, 00:00

  • PSN6 CHILDRENS ATOPIC DERMATITIS- PHARMACOECONOMIC COST ANALYSIS

    Nov 1, 2003, 00:00

  • PRP11 THE VALIDITY OF THE WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE FOR PATIENTS WITH ASTHMA (WPAIASTHMA)- RESULTS FROM A WEB-BASED STUDY

    Nov 1, 2003, 00:00

  • PIN19 ECONOMIC IMPACT OF ANTIRETROVIRAL DRUG PRICE REDUCTIONS IN NINE LATIN AMERICAN COUNTRIES

    Nov 1, 2003, 00:00

  • PAE7 VISION IMPAIRMENT AS AN INDEPENDENT RISK FACTOR OF INSTITUTIONALIZATION

    Nov 1, 2003, 00:00

  • PCN21 COMPARISON OF PAIN OUTCOMES AND HRQL USING THE TREATMENT OUTCOMES IN PAIN SURVEY (TOPS) IN CANCER-RELATED PAIN

    Nov 1, 2003, 00:00

  • PAE9 COST AND EFFECTIVENESS OF BRINZOLAMIDE VERSUS DORZOLAMIDE IN THE TREATMENT OF GLAUCOMA- AN ANALYSIS CONDUCTED USING THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

    Nov 1, 2003, 00:00

  • PMD37 RECOMMENDATIONS TO THE EUROPEAN REGULATORS FOR THE CROSS-CULTURAL ADAPTATION OF PRO MEASURES

    Nov 1, 2003, 00:00

  • PAE10 COMPARISON OF THE CLINICAL EFFICACY AND COST-EFFECTIVENESS OF LUMIGAN AND XALATAN IN THE TREATMENT OF GLAUCOMA

    Nov 1, 2003, 00:00

  • PDB19 ADVANCED TOOLS FOR ALLOCATION OF MEDICAL PRODUCTS- ECONOMIC EVALUATION OF THE 'HOMECARE' PROGRAMME

    Nov 1, 2003, 00:00

  • PAE8 SCORING OF VISUAL FIELD MEASURED THROUGH HUMPHREY PERIMETRY- PRINCIPAL COMPONENT VARIMAX ROTATION FOLLOWED BY CLUSTERING ANALYSIS

    Nov 1, 2003, 00:00

  • PSN4 ECONOMIC EVALUATION OF TACROLIMUS OINTMENT VERSUS CURRENT CARE IN MODERATE TO SEVERE ATOPIC DERMATITIS

    Nov 1, 2003, 00:00

  • PDB15 RISK OF CONGESTIVE HEART FAILURE IN TYPE 2 DIABETICS EXPOSED TO PIOGLITAZONE VS INSULIN-A MATCHED COHORT ANALYSIS

    Nov 1, 2003, 00:00

  • PMH22 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY- ITALIAN RESULTS

    Nov 1, 2003, 00:00

  • PAR14 THE COST OF OSTEOPOROTIC FRACTURES IN FEMALES IN THE UK- AN EPIDEMIOLOGICAL MODEL

    Nov 1, 2003, 00:00

  • PUK9 ECONOMICAL IMPACT OF SACRAL NERVE STIMULATION THERAPY IN 62 PATIENTS WITH LOWER URINARY TRACT DYSFUNCTION

    Nov 1, 2003, 00:00

  • PIN8 PROSPECTIVE STUDY ON ACUTE LOWER RESPIRATORY TRACT INFECTIONS IN GERMAN CHILDREN YOUNGER THAN 3 YEARS (PRI.DE)-ECONOMIC IMPACT OF HOSPITALIZED CASES

    Nov 1, 2003, 00:00

  • CV9 A HEALTH ECONOMIC EVALUATION OF N-3 POLYUNSATURATED FATTY ACIDS (PUFA) IN THE SECONDARY PREVENTION AFTER MI

    Nov 1, 2003, 00:00

  • PIN2 ASSOCIATION BETWEEN UNSUCCESSFUL INITIAL EMPIRIC ANTIBIOTIC THERAPY AND HEALTH CARE RESOURCE USE AMONG PATIENTS UNDERGOING SURGERY FOR COMMUNITY-ACQUIRED INTRA-ABDOMINAL INFECTIONS IN SPAIN

    Nov 1, 2003, 00:00

  • PIN5 REGIONAL ANTIBIOTIC PRESCRIBING GUIDELINE ADHERENCE RESULTS

    Nov 1, 2003, 00:00

  • PMH7 COST EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT VERSUS CARE AS USUAL FOR PANIC DISORDER AND/OR DEPRESSION DRIVEN CHEST PAIN- PRELIMINARY RESULTS OF UNBLINDED DATA

    Nov 1, 2003, 00:00

  • PCV42 ECONOMIC ANALYSIS OF THE USE OF CONTRAST MEDIA DURING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN

    Nov 1, 2003, 00:00

  • PHP1 POTENTIAL FINANCIAL IMPACT OF ITEM RESPONSE THEORY-BASED INDICATIONS FOR LONG-TERM HEALTH CARE FACILITIES

    Nov 1, 2003, 00:00

  • PDB7 THE IMPACT ON GLYCEMIC CONTROL OF DIABETIC PATIENTS BY A HOSPITAL PHARMACIST-MANAGED COMPLICANCE CLINIC IN HONG KONG

    Nov 1, 2003, 00:00

  • PCV30 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN GREEK PATIENTS WITH HYPERLIPIDAEMIA

    Nov 1, 2003, 00:00

  • PMH14 THE BURDEN OF ATTENTION DEFICIT AND HYPERACTIVITY DISORDER (ADHD) IN THE NORDIC COUNTRIES-A LITERATURE REVIEW

    Nov 1, 2003, 00:00

  • PHL12 MORE PRECISE DOSING INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN THE UK SETTING

    Nov 1, 2003, 00:00

  • PCV13 A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN PATIENTS WITH HEART FAILURE

    Nov 1, 2003, 00:00

  • PMD44 ADVANCING RISK ADJUSTMENT FOR SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA

    Nov 1, 2003, 00:00

  • PHL3 COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT- A CROSS-NATIONAL ASSESSMENT

    Nov 1, 2003, 00:00

  • PGS6 COST EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD)- THE ONE STUDY

    Nov 1, 2003, 00:00

  • MH3 HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS- RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PIN9 COST-EFFECTIVENESS OF TWO DIFFERENT VACCINATION STRATEGIES FOR THE PREVENTION OF MENINGOCOCCAL C DISEASE IN PORTUGAL

    Nov 1, 2003, 00:00

  • PCV78 QUALITY OF LIFE IN CHRONIC PATHOLOGIES IN PRIMARY CARE

    Nov 1, 2003, 00:00

  • PMH25 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2003, 00:00

  • PCV22 ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY

    Nov 1, 2003, 00:00

  • PCV40 ASSESSMENT OF THE COST OF CARDIOVASCULAR DEATH

    Nov 1, 2003, 00:00

  • PMD48 RELATIVE WEIGHTS ASSIGNED TO DRUGS AND BIOLOGICALS- OPPS METHODS AND CONCEPTS

    Nov 1, 2003, 00:00

  • PGS7 COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM

    Nov 1, 2003, 00:00

  • PCV57 COST EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY

    Nov 1, 2003, 00:00

  • PIN7 COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITALS PERSPECTIVE IN GERMANY-A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2003, 00:00

  • GD4 POTENTIAL HOSPITAL SAVINGS RELATED TO THE ADMINISTRATION OF ESOMEPRAZOLE TABLETS THROUGH GASTRIC TUBES IN PATIENTS CURRENTLY TREATED WITH INJECTABLE PPIS

    Nov 1, 2003, 00:00

  • PCV75 PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH STATIN MONOTHERAPY IN FINLAND

    Nov 1, 2003, 00:00

  • PAR4 ETANERCEPT VERSUS INFLIXIMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS- A COST-EFFECTIVENESS ANALYSIS FROM THE ITALIAN NHS PERSPECTIVE

    Nov 1, 2003, 00:00

  • PMD33 THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING- THE CASE OF ANTI-EPILEPTIC DRUGS

    Nov 1, 2003, 00:00

  • PMD6 DEVELOPMENT OF A WEB-BASED SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST CANCER IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • VV7 WILLINGNESS TO PAY FOR HEARING AIDS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PAE14 COST-EFFECTIVENESS ANALYSIS OF PMMA, SILICONE, AND ACRYLIC INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PCV8 CHOICE OF FIRST-LINE TREATMENT FOR HYPERTENSION IN THE UK- DOES CURRENT PRIMARY CARE PRACTICE REFLECT BRITISH GUIDELINES?

    Nov 1, 2003, 00:00

  • QL2 OUALITY OF LIFE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY

    Nov 1, 2003, 00:00

  • PAR3 EVALUATING THE IMPACT OF REIMBURSEMENT OF NON SELECTIVE COX2 INHIBITORS ON TOTAL DISPENSING OF SELECTED NSAID AND SELECTED DRUGS FOR ACID RELATED DISORDERS

    Nov 1, 2003, 00:00

  • PNM22 SOCIO-ECONOMIC IMPACT OF PARKINSONS DISEASE ON SPOUSES- THE COMPAS STUDY

    Nov 1, 2003, 00:00

  • PHP17 SURVEY ON DRUG VALUE ASSESSMENT AMONG PRESCRIBERS AND PAYERS IN ITALIAN HOSPITALS

    Nov 1, 2003, 00:00

  • PIN32 THE POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PMH11 PRODUCTION LOSSES IN BORDERLINE PERSONALITY DISORDER- SHORTCOMINGS IN THE STANDARD METHODS OF VALUATION

    Nov 1, 2003, 00:00

  • PCV16 EFFECTIVENESS AND COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION

    Nov 1, 2003, 00:00

  • PRP14 COST OFFSETS FROM PRESCRIPTION COVERAGE OF AGED PERSONS WITH COPD

    Nov 1, 2003, 00:00

  • CS3 INITIAL INSERTION OF A METAL STENT FOR PALLIATION OF MALIGNANT BILIARY OBSTRUCTION- A COST CONSEQUENCE ANALYSIS FOR ENGLAND, FRANCE AND SWEDEN

    Nov 1, 2003, 00:00

  • PDB20 THE IMPACT OF DIABETES TYPE 2 ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PCV70 A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA

    Nov 1, 2003, 00:00

  • PAE6 PREVALENCE AND BURDEN OF BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS- A NATION-WIDE SURVEY

    Nov 1, 2003, 00:00

  • PIN21 BUDGET IMPACT ANALYSIS OF UNIVERSAL VARICELLA VACCINATION IN GERMANY

    Nov 1, 2003, 00:00

  • PMD2 DISABILITY IN STROKE OUTCOMES RESEARCH- CLINICAL MEANING OF THE BARTHEL INDEX, THE FUNCTIONAL INDEPENDENCE MEASURE AND THE MODIFIED RANKIN SCALE

    Nov 1, 2003, 00:00

  • PHL11 DEVELOPMENT OF THE HAEMOPHILIA AGEGROUP SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Nov 1, 2003, 00:00

  • PCN5 REPORT ON RETROSPECTIVE ANALYSIS OF HEALTH CARE COSTS OF BONE FRACTURES IN WOMEN WITH EARLY STAGE BREAST CANCER

    Nov 1, 2003, 00:00

  • PMH26 QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS IN SPAIN- ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY

    Nov 1, 2003, 00:00

  • QL1 HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN AN EVIDENCE-BASED ASTHMA DISEASE MANAGEMENT PROGRAM

    Nov 1, 2003, 00:00

  • PMD21 LIFE EXPECTANCY AND THE DISCOUNTING OF HEALTH OUTCOMES

    Nov 1, 2003, 00:00

  • PMH17 HEALTH-RELATED QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE

    Nov 1, 2003, 00:00

  • PCN7 ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER

    Nov 1, 2003, 00:00

  • PHL1 HEMOGLOBIN LEVELS ASSOCIATED WITH DIAGNOSIS OF ANEMIA

    Nov 1, 2003, 00:00

  • PSN15 DURATION OF PSORIASIS AND QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PMH4 2-YEAR OUTCOMES OF RISPERDAL CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • QL3 ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE

    Nov 1, 2003, 00:00

  • RX1 PRESCRIPTION DRUG INFORMATION- A SURVEY OF THE GENERAL POPULATION IN SPAIN

    Nov 1, 2003, 00:00

  • PCV38 COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS-AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY

    Nov 1, 2003, 00:00

  • PRP9 INPATIENT MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS- HOSPITAL RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00
  • «
  • 171
  • 172 (current)
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • »